Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
542
datasets available to search
ShareScore release 0.9.0
Dataset results
542 results for “PCOS”
Research of Exenatide for Overweight/Obese PCOS Patients With IGR
ClinicalTrials.gov study NCT03352869. IPD Sharing: UNDECIDED. Countries: 1. Publications: 8.
Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS)
ClinicalTrials.gov study NCT05646199. IPD Sharing: NO. Countries: 1. Publications: 10.
Effects of Fasting Mimicking Diet (FMD) in Women With Polycystic Ovary Syndrome (PCOS)
ClinicalTrials.gov study NCT05196568. IPD Sharing: NO. Countries: 1. Publications: 21.
Screening for GDM in Women With PCOS and Controls
ClinicalTrials.gov study NCT02183558. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Rat BAT Xenotransplantation Recovers the Fertility and Metabolic Health of PCOS Mice
<p><strong>Supplementary dataset 1</strong></p> <p>This file contains datasets for all 230 overlapped DEGs (Fig. 6A and B) among RTM, MTM, and control group compared with the PCOS group in F0 model mice. It has two sheets: "F0 up-regulated DEGs" contained all DEGs that have significantly higher (|log2| > 1) expression levels in RTM, MTM, and control group than PCOS group; "F0 down-regulated DEGs" contained all DEGs that have significantly lower (|log2| > 1) expression level in RTM, MTM, and control group than PCOS group. For each gene, both FPKM of each repeat and the average FPKM of three repeats are shown.</p> <p><strong>Supplementary dataset 2</strong></p> <p>This file, corresponding to Fig. 7, contains 4 sheets of datasets for all DEGs that overlapped between human PCOS studies and corrent study. From left to right, in sheet 1, the datasets from column A-AB are for the DEGs in current study; the datasets from column AD-BL are for the DEGs in Lan et al (36). In sheet 2, the datasets from column A-AA are for the DEGs in our study; the datasets from column AC-AI are for the DEGs in Wissing et al (37). In sheet 3, the datasets from column A-AB are for the DEGs in our study; the datasets from column AD-AL are for the DEGs in Lu et al (38). In sheet 4, the datasets from column A-AB are for the DEGs in our study; the datasets from column AD-AG are for the DEGs in Kaur et al (39). For a clear distinguishment between our data and the reference data, column AC in sheet 1, column AB in sheet 2, column AC in sheet 3, and column AC in sheet 4 are left blank and highlighted in green; Two columns with title "symbol" and red typed in each sheet list all overlapping DEGs between our data and reference data.</p> <p><strong>Supplementary dataset </strong><strong>3</strong></p> <p>This file contains 4 sheets. Each sheet includes KEGG information for the DEGs that overlapped between human PCOS studies and current study.</p> <p><strong>Supplementary dataset </strong><strong>4</strong></p> <p>This dataset contains all 126 overlapped DEGs (Supplementary Fig. 6A and B) among RTM, MTM, and control group compared with the PCOS group in F1 model mice. It has two sheets: "F1 up-regulated DEGs" contained all DEGs that have significantly higher (|log2| > 1) expression level in RTM, MTM, and control group than in PCOS group; "F1 down-regulated DEGs" contained all DEGs that have significantly lower (|log2| > 1) expression level in RTM, MTM, and control group than in PCOS group. For each gene, both FPKM of each repeat and the average FPKM of three repeats are shown.</p>
Dataset of Insulin sensitizers for improving endocrine metabolism in overweight women with PCOS: a network meta-analysis
<p><span><b>Objective: </b>To evaluate the efficacy of insulin sensitizers on menstrual frequency, sex hormone and metabolic parameters in overweight women with PCOS. </span></p> <p><span><b>Methods:</b> We searched multiple databases from inception to September 2019 for RCTs. Network meta-analysis was conducted using multivariate random effects method. </span></p> <p><span><b>Results:</b> 14 trials reporting on 619 women were included. Compared with metformin, metformin + TZDs was more superior in menstrual recovery (WMD 3.68, 95% CrI 1.65 to 8.20), metformin + GLP-1 receptor agonists was more effective in decreasing AND (WMD -2.53, 95% CrI -3.96 to -1.09), both metformin + GLP-1 receptor agonists (WMD 9.22, 95% CrI 5.46 to 12.98) and metformin + TZDs (WMD 4.30, 95% CrI 0.78 to 7.82) were more effective in increasing SHBG, while TZDs was less effective in decreasing BMI (WMD 1.69, 95% CrI 0.72 to 2.66). Compared with GLP-1 receptor agonists, metformin + GLP-1 receptor agonists was associated with higher SHBG (WMD 7.80, 95% CrI 4.75 to 10.85), lower FT (WMD -1.77, 95% CrI -3.25 to -0.29), lower AND (WMD -2.70, 95% CrI -3.91 to -1.50) and lower FG (WMD -0.41, 95% CrI -0.73 to -0.08).</span></p> <p><span><b>Conclusion: </b>For overweight women with PCOS, both metformin combined with GLP-1 receptor agonists and metformin combined with TZDs appear superior to monotherapy in improving hyperandrogenemia. Metformin combined with TZDs could be particularly effective in promoting the recovery of menstruation. Metformin combined with GLP-1 receptor agonists has additional advantage in improving fasting glucose when compared with GLP-1 receptor agonists alone. TZDs is inferior to metformin in decreasing BMI.</span></p>
Data from: Hyperandrogenism and insulin resistance-induced fetal loss: evidence for placental mitochondrial abnormalities and elevated ROS production in pregnant rats that mimic the clinical features of PCOS
Women with polycystic ovary syndrome (PCOS) commonly suffer from miscarriage, but the underlying mechanism of PCOS‐induced fetal loss during pregnancy remains obscure and specific therapies are lacking. We used pregnant rats treated with 5α‐dihydrotestosterone (DHT) and insulin to investigate the impact of hyperandrogenism and insulin resistance on fetal survival and to determine the molecular link between PCOS conditions and placental dysfunction during pregnancy. Our study shows that pregnant rats chronically treated with a combination of DHT and insulin exhibited endocrine aberrations such as hyperandrogenism and insulin resistance that are strikingly similar to those in pregnant PCOS patients. Of pathophysiological significance, DHT+insulin‐treated pregnant rats had greater fetal loss and subsequently decreased litter sizes compared to normal pregnant rats. This negative effect was accompanied by impaired trophoblast differentiation, increased glycogen accumulation, and decreased angiogenesis in the placenta. Mechanistically, we report that over‐production of reactive oxygen species (ROS) in the placenta, mitochondrial dysfunction, and disturbed SOD1 and Keap1/Nrf2 antioxidant responses constitute important contributors to fetal loss in DHT+insulin‐treated pregnant rats. Many of the molecular pathways leading to placental abnormalities and fetal loss in DHT+insulin treatment were also seen in pregnant rats treated with DHT alone, whereas pregnant rats treated with insulin alone often exerted distinct effects on placental gene expression compared to insulin treatment in combination with DHT. We also found that treatment with the antioxidant N‐acetylcysteine (NAC) improved fetal survival in DHT+insulin‐treated pregnant rats, an effect related to changes in Keap1/Nrf2 and NFκB signaling. However, NAC administration resulted in fetal loss in normal pregnant rats, most likely due to PCOS‐like endocrine abnormality induced by the treatment. Our results suggest that the deleterious effects of hyperandrogenism and insulin resistance on fetal survival are related to a constellation of mitochondrial‐ROS‐SOD1/Nrf2 changes in the placenta. Our findings also suggest that physiological levels of ROS are required for normal placental formation and fetal survival during pregnancy.
Figure 6 from: Shannag S, Nuseir K, Tahaineh L, Hananeh W (2024) Curcumin is comparable to metformin for the treatment of PCOS in rats: a preclinical study. Pharmacia 71: 1-10. https://doi.org/10.3897/pharmacia.71.e119708
Figure 6 Ovarian section from G6 group showing disrupted follicular development, lack of corpora lutea and presence of follicular cysts.
Figure 3 from: Shannag S, Nuseir K, Tahaineh L, Hananeh W (2024) Curcumin is comparable to metformin for the treatment of PCOS in rats: a preclinical study. Pharmacia 71: 1-10. https://doi.org/10.3897/pharmacia.71.e119708
Figure 3 Hormonal and metabolic serum levels over time. Changes in serum levels of testosterone, estradiol, progesterone, and glucose before and after treatment with metformin, curcumin, metformin + curcumin, and olive oil compared to control rats' side by side. Data expressed as mean ± SEM (n = 16–17).
Figure 5 from: Shannag S, Nuseir K, Tahaineh L, Hananeh W (2024) Curcumin is comparable to metformin for the treatment of PCOS in rats: a preclinical study. Pharmacia 71: 1-10. https://doi.org/10.3897/pharmacia.71.e119708
Figure 5 Ovarian section from G3 group showing multiple variably sized follicular cysts with disrupted normal follicular development.
Figure 2 from: Shannag S, Nuseir K, Tahaineh L, Hananeh W (2024) Curcumin is comparable to metformin for the treatment of PCOS in rats: a preclinical study. Pharmacia 71: 1-10. https://doi.org/10.3897/pharmacia.71.e119708
Figure 2 Hormonal and metabolic serum levels. Changes in serum levels of testosterone, estradiol, progesterone, and glucose before and after treatment with metformin, curcumin, metformin + curcumin, and olive oil compared to control rats. Data expressed as mean ± SEM (n = 16–17). *Significantly different form control. A. Testosterone levels in ng/ml following letrozole injections and before treatment at age 9 weeks; B. Estradiol levels in pg/ml following letrozole injections and before treatment at age 9 weeks; C. Progesterone levels in ng/ml following letrozole injections and before treatment at age 9 weeks; D. Glucose serum levels mg/dl following letrozole injections and before treatment at age 9 weeks; E. Testosterone levels in ng/ml following treatment at age 12 weeks; F. Estradiol levels in pg/ml following treatment at age 12 weeks; G. Progesterone levels in ng/ml following treatment at age 12 weeks; H. Glucose serum levels mg/dl following treatment at age 12 weeks.
Figure 4 from: Shannag S, Nuseir K, Tahaineh L, Hananeh W (2024) Curcumin is comparable to metformin for the treatment of PCOS in rats: a preclinical study. Pharmacia 71: 1-10. https://doi.org/10.3897/pharmacia.71.e119708
Figure 4 Ovarian section from control group showing different stages of follicular development and normal ovarian morphology.
Figure 1 from: Shannag S, Nuseir K, Tahaineh L, Hananeh W (2024) Curcumin is comparable to metformin for the treatment of PCOS in rats: a preclinical study. Pharmacia 71: 1-10. https://doi.org/10.3897/pharmacia.71.e119708
Figure 1 Changes in body weight before (DI, week 6) PCOS induction, after PCOS induction (T, week 9), and following treatments (sac, week 12) with metformin, curcumin, combination of met +cur and olive oil. Data expressed as mean ± SEM (n = 16–17). ** significant difference from control group.
Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)
ClinicalTrials.gov study NCT01154192. IPD Sharing: NO. Countries: 1. Publications: 0.
Ultrasound Three-dimensional Characterization of Ovarian Morphology in Women With Polycystic Ovary Syndrome (PCOS)
ClinicalTrials.gov study NCT02402413. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Metformin Treatment in Polycystic Ovary Syndrome (PCOS)
ClinicalTrials.gov study NCT02198417. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility
ClinicalTrials.gov study NCT05952882. IPD Sharing: Not stated. Countries: 0. Publications: 27.
Metformin vs Inositol vs Diet vs Combination Therapy in PCOS
ClinicalTrials.gov study NCT07380841. IPD Sharing: YES. Countries: 1. Publications: 0.
Pilot Study:Role of Dietary Fiber in PCOS Anovulation
ClinicalTrials.gov study NCT00703092. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese
ClinicalTrials.gov study NCT07326111. IPD Sharing: YES. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.